Your session is about to expire
← Back to Search
mRNA Flu Vaccine for Flu
Study Summary
This trial tests the safety and effectiveness of a new flu vaccine given as a single shot for adults 18+ compared to existing vaccines.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 4 trial • 267 Patients • NCT05007041Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Media Library
- I cannot become pregnant or agree to use birth control during and after the study.I am at least 18 years old (21 if in Puerto Rico) on the day I join the study.Have you had a flu vaccine in the last 6 months? If your answer is yes, you will be excluded from the study.
- Group 1: Group 1: Quadrivalent Influenza mRNA Vaccine MRT5413 low dose
- Group 2: Group 2: Quadrivalent Influenza mRNA Vaccine MRT5413 medium dose
- Group 3: Group 3: Quadrivalent Influenza mRNA Vaccine MRT5413 high dose
- Group 4: Group 4: RIV4
- Group 5: Group 5: QIV-SD
- Group 6: Group 6: QIV-HD
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are applicants currently being sought for enrollment in this research project?
"According to clinicaltrials.gov, the recruitment period for this experiment is ongoing - it was initially listed on December 6th 2022 and has recently been updated in that same month."
What is the aggregate number of participants in this clinical trial?
"Affirmative. The clinical trial is still in the process of selecting participants and pertinent information can be found on clinicaltrials.gov. It was first published on December 6th, 2022 and has been recently revised with a goal to recruit 682 individuals from two distinct medical facilities."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
How responsive is this trial?
Typically responds via
Most responsive sites:
- Elligo Health Research, Inc.-Site Number:8400002: < 48 hours
Average response time
- < 2 Days
Share this study with friends
Copy Link
Messenger